Safety and Feasibility of Minocycline in the Treatment of Traumatic Brain Injury (TBI)

Exclusion Criteria

• •Participant is a female;
• •Participants, guardians or legal representatives who are unwilling to cooperate with the investigation;
• •Participants who have received any other investigational drug within 30 days of injury;
• •Participants known to have severe ischemic heart disease or congestive heart failure, myocardial infarction, spinal cord injury with ongoing deficits, cancer or any other severe illnesses that in the opinion of the investigator would affect the assessment of therapy;
• •Participants with an ongoing neurological disease/condition or previous stroke or TBI;
• •Known clinical sequelae of spinal cord injury;
• •Massive cerebral hemisphere or brainstem hematoma, incompatible with survival;
• •History of major depression requiring the use of the medication at the time of injury;
• •Multiple trauma which in the opinion of the investigator, would jeopardize the assessment of therapy;
• •Participants who have any type of penetrating head injury;
• •Participants receiving chronic steroid treatment;
• •Participants receiving isotretinoin;
• •Lack of informed consent signed by either the participant or the subject's legal representative;
• •Prior TBI, brain tumor, cerebral vascular event, or other stable brain insult;
• •Prior history of Pseudotumor cerebri ;
• •Patients with known renal failure, BUN/ Creatinine 20:1; creatinine \> 2 mg/dl;
• •Patients with known hepatic failure, AST/ALT\> 3 x Upper Limit of Normal;
• •Thrombocytopenia \< 75,000/mm;
• •Known allergy or sensitivity to any of the tetracyclines or any of the components of the product formulation.